ATE84414T1 - Verwendung von gamma-linolensaeure und verwandten verbindungen zur herstellung eines arneimittels zur behandlung von komplikationen bei diabetes mellitus. - Google Patents

Verwendung von gamma-linolensaeure und verwandten verbindungen zur herstellung eines arneimittels zur behandlung von komplikationen bei diabetes mellitus.

Info

Publication number
ATE84414T1
ATE84414T1 AT86307529T AT86307529T ATE84414T1 AT E84414 T1 ATE84414 T1 AT E84414T1 AT 86307529 T AT86307529 T AT 86307529T AT 86307529 T AT86307529 T AT 86307529T AT E84414 T1 ATE84414 T1 AT E84414T1
Authority
AT
Austria
Prior art keywords
complications
gamma
linolenic acid
treatment
diabetes mellitus
Prior art date
Application number
AT86307529T
Other languages
German (de)
English (en)
Inventor
David Frederick Horrobin
Charles Stewart
Hugh Carmichael
Goran A Jamal
Original Assignee
Efamol Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Efamol Holdings filed Critical Efamol Holdings
Application granted granted Critical
Publication of ATE84414T1 publication Critical patent/ATE84414T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT86307529T 1985-10-02 1986-10-01 Verwendung von gamma-linolensaeure und verwandten verbindungen zur herstellung eines arneimittels zur behandlung von komplikationen bei diabetes mellitus. ATE84414T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB858524275A GB8524275D0 (en) 1985-10-02 1985-10-02 Pharmaceutical & dietary compositions
EP86307529A EP0218460B1 (en) 1985-10-02 1986-10-01 Use of gamma-linolenic acid and related compounds for the manufacture of a medicament for the treatment of complications of diabetes mellitus.

Publications (1)

Publication Number Publication Date
ATE84414T1 true ATE84414T1 (de) 1993-01-15

Family

ID=10586062

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86307529T ATE84414T1 (de) 1985-10-02 1986-10-01 Verwendung von gamma-linolensaeure und verwandten verbindungen zur herstellung eines arneimittels zur behandlung von komplikationen bei diabetes mellitus.

Country Status (14)

Country Link
US (1) US4826877A (cg-RX-API-DMAC7.html)
EP (1) EP0218460B1 (cg-RX-API-DMAC7.html)
JP (1) JPS6296421A (cg-RX-API-DMAC7.html)
AT (1) ATE84414T1 (cg-RX-API-DMAC7.html)
AU (1) AU586286B2 (cg-RX-API-DMAC7.html)
CA (1) CA1279824C (cg-RX-API-DMAC7.html)
DE (1) DE3687501T2 (cg-RX-API-DMAC7.html)
ES (1) ES2043601T3 (cg-RX-API-DMAC7.html)
GB (1) GB8524275D0 (cg-RX-API-DMAC7.html)
GR (1) GR3007043T3 (cg-RX-API-DMAC7.html)
HK (1) HK129393A (cg-RX-API-DMAC7.html)
IE (1) IE59445B1 (cg-RX-API-DMAC7.html)
SG (1) SG115193G (cg-RX-API-DMAC7.html)
ZA (1) ZA867386B (cg-RX-API-DMAC7.html)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2197199B (en) * 1986-11-13 1991-04-03 Efamed Medicament for treatment of pregnancy-induced hypertension.
GB8710780D0 (en) * 1987-05-07 1987-06-10 Scras Opthalmological application of eicosapentaenoic acid
US5225441A (en) * 1987-06-18 1993-07-06 Block Drug Company, Inc. Treatment of periodontal disease
JP2524217B2 (ja) * 1988-04-18 1996-08-14 マルハ株式会社 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
US6140304A (en) * 1988-09-28 2000-10-31 Eicotech Corporation Method of and nutritional and pharmaceutical compositions for reduction of hyperinsulinemia
AU620929B2 (en) * 1988-10-27 1992-02-27 Bar-Ilan University Method and compositions for treating alzheimer's disease, related dementias and epilepsy
GB8916734D0 (en) * 1989-07-21 1989-09-06 Efamol Holdings Pharmaceutical and dietary uses of fatty acids
US5407957A (en) * 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
ES2033193B1 (es) * 1990-10-30 1994-01-16 Ganadera Union Ind Agro Mezcla grasa para nutricion infantil y de adultos.
IL100733A (en) * 1991-01-24 1995-12-31 Martek Corp Preparations containing a mixture of microbial oils and their preparation
GB9111900D0 (en) * 1991-06-03 1991-07-24 Efamol Holdings Fatty acid compositions
JPH0649479A (ja) * 1992-07-28 1994-02-22 Maruha Corp ω−３不飽和脂肪酸系化合物の安定化法
GB9300125D0 (en) * 1993-01-06 1993-03-03 Scotia Holdings Plc Compositions containing esters of unsaturated fatty acids
AU693450B2 (en) * 1993-06-09 1998-07-02 Martek Biosciences Corporation Methods and pharmaceutical compositions useful for treating neurological disorders
US20050027004A1 (en) * 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
IT1265340B1 (it) * 1993-07-14 1996-11-22 Istituto Biochimico Italiano Sostanze inibenti l'adp-ribosilazione proteica atte alla prevenzione delle complicanze del diabete mellito.
EP0734723A4 (en) * 1993-12-29 2001-04-11 Kowa Tekuno Sachi Co Ltd THERAPEUTIC COMPOSITION USEFUL FOR TREATING HYPERPARATHYROIDIA OF A PATIENT ON ARTIFICIAL DIALYSIS
JPH07143862A (ja) * 1994-05-06 1995-06-06 Maruha Corp 脳機能改善効果を有する機能性食品。
GB9412925D0 (en) * 1994-06-28 1994-08-17 Scotia Holdings Plc Combination of aldose reductase inhibitors with gamma-linolenic (GLA) dihomogammalinolenic (DGLA) or arachidonic (AA) acids in the treatment of diabetic
AU711482B2 (en) * 1994-06-28 1999-10-14 Scotia Holdings Plc Compositions for treatment of diabetic complications
US5968809A (en) * 1997-04-11 1999-10-19 Abbot Laboratories Methods and compositions for synthesis of long chain poly-unsaturated fatty acids
GB9715444D0 (en) 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
IL125731A (en) 1998-08-11 2004-06-20 Zvi Yehuda Acylates which are products of neurotransmitters and essential fatty acids, pharmaceutical compositions containing them, use of such acylates in the manufacture of medicaments, and method for treating nervous diseases in non-human animals
US20030163845A1 (en) * 1998-09-02 2003-08-28 Pradip Mukerji Elongase genes and uses thereof
US6677145B2 (en) 1998-09-02 2004-01-13 Abbott Laboratories Elongase genes and uses thereof
DE19903095C2 (de) * 1999-01-27 2003-05-22 Nutrinova Gmbh Gewinnung von gamma-Linolensäure aus Protozoen der Gattung Colpidium
US6440931B1 (en) * 1999-02-23 2002-08-27 Natural Corporation Conjugated linoleic acid in treatment and prophylaxis of diabetes
US7070970B2 (en) 1999-08-23 2006-07-04 Abbott Laboratories Elongase genes and uses thereof
EP1220669A4 (en) * 1999-10-13 2004-12-08 Marco A Chacon THERAPEUTIC MEASURE TO IMPROVE THE EFFECT OF A CALORY RESTRICTION
CA2301158A1 (en) * 2000-03-24 2001-09-24 Stephen J. Allen Screening methods for compounds useful for modulating lipid metabolism in disease
EP1197550A3 (en) * 2000-08-25 2002-11-20 Pfizer Products Inc. Methods and compositions for diagnosing and treating disorders involving angiogenesis
US6635451B2 (en) * 2001-01-25 2003-10-21 Abbott Laboratories Desaturase genes and uses thereof
US7045683B2 (en) 2001-05-04 2006-05-16 Abbott Laboratories Δ4-desaturase genes and uses thereof
GB0111282D0 (en) * 2001-05-09 2001-06-27 Laxdale Ltd Potentiation of therapeutic effects of fatty acids
DE60203494T2 (de) * 2001-05-30 2006-02-09 Laxdale Ltd. Verwendung von coenzym q (ubiquinone) und eikosapentaensäure (epa) für die behandlung von non-hodgkin's lymphoma und psychiatrischen oder neurologischen erkrankungen
US7211656B2 (en) 2002-01-30 2007-05-01 Abbott Laboratories Desaturase genes, enzymes encoded thereby, and uses thereof
US7622632B2 (en) 2002-05-22 2009-11-24 Monsanto Technology Llc Fatty acid desaturases from fungi
US7125672B2 (en) * 2003-05-07 2006-10-24 E. I. Du Pont De Nemours And Company Codon-optimized genes for the production of polyunsaturated fatty acids in oleaginous yeasts
US7214491B2 (en) 2003-05-07 2007-05-08 E. I. Du Pont De Nemours And Company Δ-12 desaturase gene suitable for altering levels of polyunsaturated fatty acids in oleaginous yeasts
US7238482B2 (en) 2003-05-07 2007-07-03 E. I. Du Pont De Nemours And Company Production of polyunsaturated fatty acids in oleaginous yeasts
GB0311081D0 (en) * 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
CA2436650A1 (en) * 2003-08-06 2005-02-06 Naturia Inc. Conjugated linolenic acid (clnatm) compositions: synthesis, purification and uses
GB2422373B (en) * 2003-08-18 2008-05-21 Btg Int Ltd Treatment of neurodegenerative conditions
FR2860720A1 (fr) * 2003-10-09 2005-04-15 Jean Pascal Conduzorgues Nouvelles compositions pharmaceutiques pour traiter la xerostomie et maladies similaires
WO2005047479A2 (en) 2003-11-12 2005-05-26 E.I. Dupont De Nemours And Company Delta-15 desaturases suitable for altering levels of polyunsaturated fatty acids in oilseed plants and oleaginous yeast
ES2541537T3 (es) 2004-04-16 2015-07-21 Monsanto Technology, Llc Expresión de desaturasas de ácido graso en maíz
US20070265341A1 (en) * 2004-07-01 2007-11-15 The Schepens Eye Research Institute Inc. Compositions and methods for treating eye disorders and conditions
US20060009522A1 (en) * 2004-07-01 2006-01-12 Reza Dana Compositions and methods for treating eye disorders and conditions
DE102004034640A1 (de) 2004-07-16 2006-02-16 Institut für Molekular- und Systemmedizin Verfahren zur systemischen Biokorrektur eines Organismus
US7138391B2 (en) * 2004-08-09 2006-11-21 Silverbrook Research Pty Ltd Hydrophilizable and hydrophilic cyanine dyes
US7456270B2 (en) * 2004-09-01 2008-11-25 Abbott Laboratories Δ6-desaturase genes and uses thereof
GB0425932D0 (en) * 2004-11-25 2004-12-29 Btg Int Ltd Structured phospholipids
GB0504333D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Treatment of cytokine dysregulation
GB0504362D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
EP1967198B1 (en) * 2007-03-07 2009-05-13 Indena S.P.A. Formulations containing cynara scolymus and phaseolus vulgaris extracts which are useful in the treatment of obesity
WO2010042510A1 (en) 2008-10-06 2010-04-15 Abbott Laboratires Delta-8 desaturase genes, enzymes encoded thereby and uses thereof
MX2011005077A (es) * 2008-11-14 2011-05-25 Bomi P Framroze Un metodo para reducir el complejo de lipoproteina-beta-2-glicopro teina 1 de baja densidad oxidado circulante para el tratamiento de ateroesclerosis.
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8188335B2 (en) 2009-07-17 2012-05-29 Abbott Laboratories Δ9-elongase for production of polyunsaturated fatty acid-enriched oils
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
MX375328B (es) * 2014-06-04 2025-03-06 Ds Biopharma Ltd Composiciones farmacéuticas que comprenden ácido dihomo-gamma-linolénico (dgla) y uso de las mismas
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4058594A (en) * 1974-04-25 1977-11-15 John Williams Immuno-suppressive agents
GB1580444A (en) * 1976-11-04 1980-12-03 Bio Oil Res Pharmaceutical compositions
IE47777B1 (en) * 1978-01-23 1984-06-13 Efamol Ltd Pharmaceutical and dietary composition comprising gamma-linolenic acids
IE49783B1 (en) * 1979-05-18 1985-12-11 Efamol Ltd Pharmaceutical and dietary composition comprising epsilon-linolenic acids
ATE11014T1 (de) * 1981-07-14 1985-01-15 Efamol Limited Pharmazeutische und diaetetische zusammensetzung zur erhoehung der serie-l-pg-produktion.
DE3366506D1 (en) * 1982-03-01 1986-11-06 Efamol Ltd Pharmaceutical composition
DE3368377D1 (en) * 1982-04-16 1987-01-29 Nestle Sa Lipid composition for oral, enteral or parenteral feeding
US4472432A (en) * 1982-05-12 1984-09-18 Inabata & Co., Ltd. Medicinal use of α,β-unsaturated fatty acids
IL69782A (en) * 1982-09-22 1987-12-20 Sentrachem Ltd Compositions for preventing cancerous conditions comprising precursors of eicosanoid mixtures and a dietary supplement containing them
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
GB8326130D0 (en) * 1983-09-29 1983-11-02 Efamol Ltd Topical preparations containing tars and fatty acids
FR2558154B1 (fr) * 1984-01-16 1986-08-29 Pf Medicament Acides gras ramifies en c10 a c20 utiles en tant que medicaments, et leur procede de preparation

Also Published As

Publication number Publication date
HK129393A (en) 1993-12-03
IE59445B1 (en) 1994-02-23
IE862543L (en) 1987-04-02
DE3687501D1 (de) 1993-02-25
CA1279824C (en) 1991-02-05
AU6340786A (en) 1987-04-09
US4826877A (en) 1989-05-02
EP0218460A3 (en) 1989-08-09
SG115193G (en) 1994-01-21
JPS6296421A (ja) 1987-05-02
GR3007043T3 (cg-RX-API-DMAC7.html) 1993-07-30
AU586286B2 (en) 1989-07-06
ZA867386B (en) 1987-10-28
EP0218460A2 (en) 1987-04-15
GB8524275D0 (en) 1985-11-06
EP0218460B1 (en) 1993-01-13
DE3687501T2 (de) 1993-05-19
ES2043601T3 (es) 1994-01-01

Similar Documents

Publication Publication Date Title
ATE84414T1 (de) Verwendung von gamma-linolensaeure und verwandten verbindungen zur herstellung eines arneimittels zur behandlung von komplikationen bei diabetes mellitus.
ATE73657T1 (de) Verwendung von gamma-linolensaeure und verwandten verbindungen zur herstellung eubnes arzneimittels zur behandlung von endometriose.
DE69230112D1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
BG60261B2 (en) Lon-acting formulation of cefaclor
CA2117199A1 (en) Method for the treatment of the complications and pathology of diabetes
ZA885192B (en) Pharmaceutical preparations
CA2066943A1 (en) Heterocyclically substituted phenylacetic acid derivatives, processes for their preparation and their use in medicaments
SE8403487L (sv) Farmaceutisk komposition
ATE135375T1 (de) Glykosaminoglykan-modifiertes protein, verfahren zu dessen herstellung und pharmazeutische zubereitungen, die es enthalten
WO1996015784A3 (de) 2,2-dichloralkancarbonsäuren, verfahren zu ihrer herstellung diese enthaltende arzneimittel, und ihre verwendung zur behandlung der insulinresistenz
ATE143601T1 (de) Verwendung von rifamycinderivaten zur herstellung eines arzneimittels zur behandlung der toxoplasmose
EP0329008A3 (de) Cephalosporinderivative und Verfahren zu ihrer Herstellung
DE69015910D1 (de) Pharmazeutische Verwendung von Fettsäuren.
DE59206924D1 (de) Ein flurbiprofen enthaltendes akutarzneimittel und seine verwendung
KR890008136A (ko) 항균성 9-데옥소-9a-알릴 및 프로파길-9a-아자-9a-호모에리트로 마이신 A 유도체
CA2038025A1 (en) Optically active alkylenedioxybenzene derivatives and their use in therapy
DE3681656D1 (de) Verwendung von linol- oder linolensaeure-metaboliten zur behandlung vom praemenstruellen syndrom.
IE46171L (en) N-pyrrolidinylmethylbenzamide derivative.
HUT47375A (en) Fungicide compositions containing /2-cyano-2-oximino-acetyl/-aminoacid derivatives as active components and process for producing the active components
IL106107A0 (en) Imidazolyl-substituted cyclohexane derivatives,their preparation and pharmaceutical compositions containing them
ATE100102T1 (de) Substituierte derivate von 20,21dinoreburnamenin, verfahren zur herstellung und so hergestellte zwischenprodukte, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammenstellungen.
RU94045839A (ru) Производные 3-(фенилалкиламиноалкилокси)-5-фенилпиразола, а также способ и промежуточные вещества для их получения, лекарственное средство, содержащее эти соединения
ATE6124T1 (de) Arzneimittel zur lokalen behandlung des glaukoms.
MX9703359A (es) Acidos 2,2-dicloroalcancarboxilicos, proceso para su preparacion, medicamentos que los contienen y su uso para tratar resistencia a la insulina.
GB1361199A (en) Mercaptoalcohols and process for their manufacture

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee